Evangelismos S A

Az itteni vizsgálatok

Miről szól a helyszín 90 vizsgálata, a regiszteri adatlapjaik szerint.

Betegségek

• Mielóma multiplex21 vizsgálat
• Colitis ulcerosa13 vizsgálat
• Crohn-betegség7 vizsgálat
• Magas vérnyomás7 vizsgálat
• Pulmonális artériás hipertónia6 vizsgálat
• 2-es típusú cukorbetegség4 vizsgálat
• Elhízás4 vizsgálat
• Krónikus limfoid leukémia (CLL)4 vizsgálat
• Akut limfoid leukémia (ALL)3 vizsgálat
• Diffúz nagy B-sejtes limfóma (DLBCL)3 vizsgálat
• Primer biliáris cholangitis (PBC)3 vizsgálat
• Zsírmáj (MASLD/MASH)3 vizsgálat
• és még 21

Fázis

• 3. fázis60 vizsgálat
• 2. fázis20 vizsgálat
• 2/3. fázis6 vizsgálat
• 1. fázis3 vizsgálat
• 1/2. fázis1 vizsgálat

Állapot

• Toboroz38 vizsgálat
• Lezárult23 vizsgálat
• Fut, nem toboroz19 vizsgálat
• Még nem toboroz10 vizsgálat

Fő szponzor

• Merck Sharp & Dohme LLC11 vizsgálat
• GlaxoSmithKline8 vizsgálat
• Janssen Research & Development, LLC7 vizsgálat
• Novo Nordisk A/S5 vizsgálat
• Amgen Inc.3 vizsgálat
• és még 40

Futó vizsgálatok

• Még nem toboroz

  A pivotal clinical study to investigate the safety and efficacy of efimosfermin compared with placebo in adult participants with compensated cirrhosis due to Metabolic dysfunction-associated steatohepatitis (MASH)

  2026-525755-82-00· 3. fázis· Glaxosmithkline Research & Development Limited· Forrás

• Még nem toboroz

  A study to investigate safety and efficacy of efimosfermin compared with placebo in adult participants with compensated cirrhosis (stage F4 fibrosis) due to MASH (NEBULA-2)

  2026-525757-37-00· 3. fázis· Glaxosmithkline Research & Development Limited· Forrás

• Toboroz

  Efficacy and Safety of Once-Daily Oral ASC30 Compared with Placebo in Participants with Obesity or Overweight with Type 2 Diabetes Mellitus

  2026-526336-39-00· 3. fázis· Ascletis Pharma (China) Co. Ltd.· Forrás

• Toboroz

  Efficacy and Safety of Once-Daily Oral ASC30 Compared with Placebo in Participants with Obesity or Overweight with Weight-Related Comorbidities

  2026-526172-23-00· 3. fázis· Ascletis Pharma (China) Co. Ltd.· Forrás

• Toboroz

  A Phase 3 Study Comparing Ramantamig plus Daratumumab Versus DVRd or DRd in Participants With NDMM for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

  2026-526654-14-01· 3. fázis· Janssen Cilag International· Forrás

• Toboroz

  A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned

  NCT07665450· 3. fázis· Janssen Research & Development, LLC· Forrás

• Toboroz

  Study of Saroglitazar Magnesium for PBC Patients With Incomplete Response or Intolerant to UDCA Therapy

  NCT07424677· 3. fázis· Zydus Therapeutics Inc.· Forrás

• Toboroz

  A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)

  NCT07481981· 3. fázis· Insmed Incorporated· Forrás

• Toboroz

  A Phase 3 Randomized Study Comparing JNJ-79635322 versus Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma

  2025-523815-12-00· 3. fázis· Janssen Cilag International· Forrás

• Toboroz

  A study of LY4268989 in participants with Moderately to Severely Active Ulcerative Colitis (EMERALD-3)

  2025-524404-29-00· 2. fázis· Eli Lilly & Co.· Forrás

• Toboroz

  A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)

  NCT07634471· 2/3. fázis· Merck Sharp & Dohme LLC· Forrás

• Toboroz

  A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease.

  NCT07596849· 3. fázis· argenx· Forrás

• Meghívásos bevonás

  Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBD

  NCT07652294· 2. fázis· Spyre Therapeutics, Inc.· Forrás

• Toboroz

  A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

  NCT07518186· 3. fázis· Janssen Research & Development, LLC· Forrás

• Toboroz

  A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT07577856· 3. fázis· Janssen Research & Development, LLC· Forrás

• Toboroz

  A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease

  NCT07577843· 3. fázis· Janssen Research & Development, LLC· Forrás

• Toboroz

  A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight

  NCT07564414· 3. fázis· Novo Nordisk A/S· Forrás

• Toboroz

  A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)

  NCT07393282· 3. fázis· Regeneron Pharmaceuticals· Forrás

• Toboroz

  A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)

  NCT07570173· 2/3. fázis· Merck Sharp & Dohme LLC· Forrás

• Toboroz

  AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain

  NCT07509307· 3. fázis· Novo Nordisk A/S· Forrás

• Toboroz

  A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)

  NCT07227311· 2. fázis· GlaxoSmithKline· Forrás

• Toboroz

  A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)

  NCT07355218· 3. fázis· EMD Serono Research & Development Institute, Inc.· Forrás

• Toboroz

  Long-Term Study to Evaluate the Safety and Efficacy in Participants With Primary Biliary Cholangitis of Saroglitazar Magnesium-V on Clinical Outcomes

  NCT07216235· 3. fázis· Zydus Therapeutics Inc.· Forrás

• Toboroz

  A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002)

  NCT07463183· 2. fázis· Merck Sharp & Dohme LLC· Forrás

• Toboroz

  MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)

  NCT07431827· 3. fázis· Merck Sharp & Dohme LLC· Forrás

• Toboroz

  A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

  NCT07258511· 3. fázis· Janssen Research & Development, LLC· Forrás

• Toboroz

  A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

  NCT07222761· 3. fázis· Regeneron Pharmaceuticals· Forrás

• Toboroz

  A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant

  NCT06932562· 3. fázis· European Myeloma Network B.V.· Forrás

• Toboroz

  KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)

  NCT07252739· 2. fázis· Merck Sharp & Dohme LLC· Forrás

• Toboroz

  A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH

  NCT07221188· 3. fázis· GlaxoSmithKline· Forrás

• Toboroz

  A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease

  NCT07196722· 2/3. fázis· Janssen Research & Development, LLC· Forrás

• Fut, nem toboroz

  A Phase 3 Trial Comparing Whether BEM/RZR is Similar to SOF/VEL in Patients with Hepatitis C Virus Infection

  2025-521096-31-00· 3. fázis· Atea Pharmaceuticals Inc.· Forrás

• Fut, nem toboroz

  A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis

  NCT07196748· 3. fázis· Janssen Research & Development, LLC· Forrás

• Toboroz

  A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008)

  2024-518296-56-00· 3. fázis· Merck Sharp & Dohme LLC· Forrás

• Toboroz

  A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)

  2024-513613-12-00· 1/2. fázis· Novartis Pharma AG· Forrás

• Toboroz

  A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis

  NCT07012395· 2. fázis· Spyre Therapeutics, Inc.· Forrás

• Toboroz

  A Double-Blind, Placebo-Controlled, Crossover Pilot Study of the Efficacy and Safety of Fluasterone Buccal Tablet in the Control of Hyperglycemia in Adults with Endogenous Cushing’s Syndrome

  2023-508322-10-00· 2. fázis· Sterotherapeutics LLC· Forrás

• Toboroz

  An Adaptive, Dose-Ranging, Phase 2 Study of Eltrekibart Given Alone or in Combination with Mirikizumab for the Treatment of Adult Patients with Moderately to Severely Active Ulcerative Colitis

  2023-507853-13-00· 2. fázis· Eli Lilly & Co.· Forrás

• Toboroz

  Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Subjects With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (CodeBreaK 301)

  2022-502352-31-00· 3. fázis· Amgen Inc.· Forrás

• Toboroz

  A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

  NCT06717347· 3. fázis· Merck Sharp & Dohme LLC· Forrás

• Toboroz

  Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).

  NCT06641414· 3. fázis· Ascentage Pharma Group Inc.· Forrás

• Toboroz

  A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

  NCT06588478· 2. fázis· Loxo Oncology, Inc.· Forrás

• Toboroz

  The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect

  NCT06058585· 3. fázis· The George Institute· Forrás

• Toboroz

  Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)

  NCT06274801· 3. fázis· Gossamer Bio USA, Inc.· Forrás

• Toboroz

  A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

  NCT06428019· 3. fázis· AbbVie· Forrás

• Toboroz

  Depemokimab Asthma Imaging and Bronchoscopy Sub-Study

  NCT06979323· 3. fázis· GlaxoSmithKline· Forrás

• Toboroz

  A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

  NCT06430801· 3. fázis· Merck Sharp & Dohme LLC· Forrás

• Toboroz

  MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

  NCT06152575· 3. fázis· Pfizer· Forrás

• Toboroz

  A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

  NCT06136559· 3. fázis· Merck Sharp & Dohme LLC· Forrás

• Toboroz

  Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis

  NCT06051617· 3. fázis· Gilead Sciences· Forrás

Showing 50 of 67.

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

• Mielóma multiplex13 toboroz
• Colitis ulcerosa6 toboroz
• Crohn-betegség3 toboroz
• Elhízás3 toboroz
• Primer biliáris cholangitis (PBC)3 toboroz
• Zsírmáj (MASLD/MASH)3 toboroz
• Akut limfoid leukémia (ALL)2 toboroz
• Krónikus limfoid leukémia (CLL)2 toboroz
• Magas vérnyomás2 toboroz
• Pulmonális artériás hipertónia2 toboroz
• Tüdőrák2 toboroz
• 2-es típusú cukorbetegség1 toboroz
• Asztma1 toboroz
• Cushing's syndrome1 toboroz
• Diffúz nagy B-sejtes limfóma (DLBCL)1 toboroz
• Follikuláris limfóma1 toboroz
• Graves' disease and hyperthyroidism1 toboroz
• Gyermekkori daganatok1 toboroz
• Krónikus vesebetegség1 toboroz
• Lupus (SLE)1 toboroz
• Mielodiszplasztikus szindróma (MDS)1 toboroz
• Osteoarthritis1 toboroz
• Szarkóma1 toboroz
• Vastagbélrák1 toboroz

Lezárt vizsgálatok

• Lezárult

  A study to compare the effect of AVT16 and Entyvio® in subjects with moderate to severe active ulcerative colitis.

  2023-507705-34-00· 3. fázis· Alvotech Swiss AG· Forrás

• Lezárult

  A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both

  NCT06534411· 3. fázis· Novo Nordisk A/S· Forrás

• Fut, nem toboroz

  A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac Disease

  NCT06557772· 2. fázis· Sanofi· Forrás

• Lezárult

  A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants with Moderate to Severe Ulcerative Colitis

  2023-506655-19-00· 2. fázis· Genentech Inc.· Forrás

• Fut, nem toboroz

  A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation

  NCT06200207· 3. fázis· Novo Nordisk A/S· Forrás

• Lezárult

  A Research Study to See How Well New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Levels in People With Type 2 Diabetes (T2D), Compared to Daily Insulin Glargine (COMBINE 4)

  NCT06269107· 3. fázis· Novo Nordisk A/S· Forrás

• Lezárult

  Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)

  NCT05934526· 3. fázis· GB002, Inc.· Forrás

• Lezárult

  A Study to Investigate MBS2320 Patients with IPF

  2023-504418-30-00· 2. fázis· Modern Biosciences Limited· Forrás

• Lezárult

  Long-term Safety and Efficacy of Efavaleukin Alfa in Subjects With Moderately to Severely Active Ulcerative Colitis

  NCT05672199· 2. fázis· Amgen Inc.· Forrás

• Lezárult

  Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial – Follow Up Long Term Extension (IMPAHCT-FUL)

  NCT05557942· 3. fázis· Aerovate Therapeutics Inc.· Forrás

• Lezárult

  A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease

  NCT05595642· 3. fázis· Hoffmann-La Roche· Forrás

• Lezárult

  Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 1)

  NCT05630807· 3. fázis· GlaxoSmithKline· Forrás

• Lezárult

  ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1

  NCT05507203· 3. fázis· Abivax S.A.· Forrás

• Lezárult

  Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial (IMPAHCT) or A Phase 2b/3, Randomized, Controlled, 24-week Dose Ranging and Confirmatory Study of AV-101 in Patients with PAH

  NCT05036135· 2/3. fázis· Aerovate Therapeutics Inc.· Forrás

• Lezárult

  A Phase 2 study of durcabtagene autoleucel, B-cell maturation Antigen (BCMA)-directed CAR-T Cells in adult participants with relapsed and refractory multiple myeloma

  NCT05172596· 2. fázis· Novartis Pharma AG· Forrás

• Lezárult

  A Phase 3 Study of Sotatercept in Newly Diagnosed Intermediate- and High-risk Pulmonary Arterial Hypertension (PAH) Patients.

  NCT04811092· 3. fázis· Acceleron Pharma Inc.· Forrás

• Lezárult

  A Study to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Subjects with Idiopathic Pulmonary Fibrosis

  NCT05032066· 2. fázis· Horizon Therapeutics Ireland Designated Activity Company· Forrás

• Lezárult

  Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma

  NCT05064358· 2. fázis· GlaxoSmithKline· Forrás

• Lezárult

  Safety and Efficacy of Efavaleukin Alfa in Subjects with Moderately to Severely Active Ulcerative Colitis

  NCT04987307· 2. fázis· Amgen Inc.· Forrás

• Lezárult

  A Study to Evaluate Zilovertamab Vedotin (MK-2140) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-004)

  NCT05144841· 2. fázis· Merck Sharp & Dohme LLC· Forrás

• Lezárult

  A Phase I Study of Belantamab Mafodotin in Multiple Myeloma Participants with Normal and Impaired Hepatic Function

  2023-509915-10-00· 1. fázis· Glaxosmithkline Research & Development Limited· Forrás

• Lezárult

  A Multicenter, Randomized, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction and Maintenance Therapy for Moderately to Severely Active Crohn’s Disease

  2024-513569-38-00· 2/3. fázis· Arena Pharmaceuticals Inc.· Forrás

• Lezárult

  Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study)

  NCT04502030· 3. fázis· Octapharma· Forrás